Life Sciences MoForum 2024 | San Diego: The State of the Life Sciences Industry

Life Sciences Moforum 2024 | San Diego: The State Of The Life Sciences Industry

Life Sciences MoForum 2024 | San Diego: The State of the Life Sciences Industry

On September 24, 2024, Morrison Foerster hosted another installment of its premier MoForum series at the firm’s San Diego office.

Mayor Todd Gloria shared his vision for San Diego’s commitment to the industry. The event featured expert panel discussions on cutting-edge scientific developments, market trends, and technological innovations. Three innovative companies showcased their breakthrough technologies and business models. Renowned keynote speaker Orly Lobel highlighted the transformative power of digital technology in shaping the future of life sciences.

Key Takeaways from the Panel’s Discussion

The Science

Karen Potter, a partner in MoFo’s Patent Strategy and Prosecution practice, moderated the Science panel. She was joined by Brendan Eckelman (Co-Founder and CSO of Inhibrx Biosciences), Michael Ports (CSO of CARGO Therapeutics), Kit Pogliano (Dean of Biological Sciences, UCSD), and Vaughn Smider (President of Applied Biomedical Science Institute). The discussion highlighted the current and emerging innovation landscape that is driving drug development in life sciences, the role of scientific collaboration in fostering innovation and how it has evolved in San Diego, and the challenges and future outlook for the life sciences sector.

The Market

Jim Krenn, co-chair of MoFo’s Emerging Companies + Venture Capital Group led the Market panel. He shared the stage with Kim Kamdar (Managing Partner of Medical Excellence Capital), Gavin Liu (Senior Director of Legal Strategic Transactions, Astellas), Niall O’Donnell (Managing Director of RiverVest Venture Partners), and Hunter Reed (Vice President of Alexandria Venture Investments). The panel discussed the current state of the life sciences venture market, including the ongoing challenges many companies raising capital continue to face as well as optimism for the future as interest rates trend downwards.

The Technology

Erin Bosman, founder and co-head of MoFo’s Artificial Intelligence Group and chair of MoFo’s Class Actions and Mass Torts Group, led an in-depth dialogue on the Technology panel with Andrés Bratt-Leal (SVP of Research & Development, Aspen Neuroscience), Andrew Burch (President of Nucleic Acid Production, Maravai LifeSciences), Brendan Daly (Senior Innovation & Licensing Manager of San Diego State University), and Doug Komen (CFO of Vektor Medical). They explored the new technologies revolutionizing life sciences, including how these technologies are benefiting companies and customers, the pace of advancement, San Diego’s infrastructure and support of life sciences, and the current challenges posed by these new technologies.

Conclusion

The MoForum program provided invaluable insights and sparked meaningful discussions in the life sciences sector. The next installment will take place in Boston in January 2025, with a special focus on women in life sciences. Stay tuned for more details.

Erin M. Bosman
Partner

Erin Bosman is chair of MoFo’s Complex Litigation + Advisement Practice Group and is a founder and co-head of the Artificial Intelligence Group. Clients value her business strategy, seeking her comprehensive counsel throughout the product life cycle, especially in high-stakes litigation and product recalls.

Erin’s clients value her litigation acumen, retaining her as national coordinating and trial counsel in class action cases and multijurisdictional and

More

Jim Krenn
Co-Chair of Emerging Companies + Venture Capital Practice

Jim Krenn is a corporate partner and co-chair of the firm’s Emerging Companies + Venture Capital Group.

Jim has extensive experience representing private and public companies and investors in significant business transactions from formation through liquidity. His practice focuses on mergers and acquisitions, venture capital financings, and emerging company counseling. His clients span a broad range of industries, with a concentration in life science and

More

Karen G Potter Ph.D.
Partner

Karen Potter is a partner in Morrison & Foerster’s Life Sciences Patent group. Her practice focuses on patent preparation, prosecution, and strategic counseling for start‑up, emerging, and established life sciences and biotechnology companies. She advises clients in the development and management of comprehensive patent portfolios that match their scientific and business objectives. Karen also helps identify and evaluate patentability, ensure freedom to operate, and perform

More

TopicsAgtechAI + RoboticsAnnouncementsAntitrustAsiaBioinformaticsBiotechBlockchainCell + Gene TherapyCFIUSCorporate + Venture CapitalCOVID-19Data AnalyticsDigital HealthEmploymentEuropean UnionFDAFinancingGlobalHealthcareIntellectual PropertyLicensing + CommercialLitigationMedical Devices + DiagnosticsPharmaPrivacy + Data SecurityProduct Liability + Class ActionRare DiseaseRegulatoryStartupUnited KingdomUnited States

Recent Posts